Integral Health Asset Management LLC Has $19.38 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Integral Health Asset Management LLC reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 350,000 shares of the company's stock after selling 25,000 shares during the quarter. Tarsus Pharmaceuticals accounts for approximately 1.7% of Integral Health Asset Management LLC's holdings, making the stock its 21st biggest position. Integral Health Asset Management LLC owned 0.92% of Tarsus Pharmaceuticals worth $19,380,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $25,000. R Squared Ltd acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $53,000. Quarry LP acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $166,000. HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at $207,000. Finally, Summit Investment Advisors Inc. raised its stake in Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after purchasing an additional 244 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer now owns 824,106 shares of the company's stock, valued at approximately $41,205,300. This represents a 0.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dianne C. Whitfield sold 2,137 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the sale, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is owned by insiders.

Tarsus Pharmaceuticals Stock Down 4.8%

TARS opened at $44.87 on Monday. The firm's 50-day simple moving average is $48.26 and its 200-day simple moving average is $49.21. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -11.78 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TARS has been the subject of several research analyst reports. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group increased their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Finally, Barclays dropped their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Tarsus Pharmaceuticals has a consensus rating of "Buy" and an average target price of $66.33.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.